Novo Nordisk Reports Cybersecurity Breach Affecting Clinical Trial Patient Data

Written By :  sheeba farhat
Published On 2026-06-12 16:53 GMT   |   Update On 2026-06-12 16:53 GMT
Advertisement

New Delhi: Novo Nordisk said on Thursday it has identified a ​security incident in which ​certain information, including patient data from some ​clinical trials, was copied externally without authorization from its internal IT systems.

The company, maker of the blockbuster weight-loss drug Wegovy, said it has launched ‌a probe ⁠with the ⁠assistance of external cybersecurity experts and is in contact with the ​relevant authorities.

"The incident affected a limited amount of information related to patients ​participating in some of our clinical trials," Novo said in its statement, without disclosing what type of trials.

The potential categories ​of personal data affected may include patient ⁠ID, year ‌of birth, sex and health or immunogenicity ​data among ​others, it added. Novo did not provide further details ⁠when contacted by Reuters.

In its statement, Novo said ​the information is not directly linked to ​any patients by name or other direct identifiers, and it does not consider the incident to enable any third party to identify participants in its clinical trials.

Knowledge of patient identity would require access to further information, which was not ‌part of the incident, the company added.

The drugmaker said it does not view the incident as ​posing any immediate ​risks to patients, ⁠but advised that they report any unusual occurrences they believe could be linked to the incident.

The company has temporarily taken certain ​internal IT systems offline, and is working to bring the affected systems back online in a controlled and safe manner.

The company's core business operations are not impacted and remain up and running, it added.

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News